Untitled record

The present invention provides an imidazoquinoline- and tetrahydroimidazoquinoline derivative having an ether and heterocyclic heteroaryl functionality at the 1-position which are useful in inducing mutants, inducing various cytokines and useful in the treatment of various conditions including viral diseases and cancer diseases. The compounds of the invention may be represented by the general formula (A), the narrower of which being the compounds of formula (I), (II), (III) and (IV) of the present invention. The present invention also provides pharmaceutical compositions containing the excipients of the invention and novel compounds of formula (IX) for the preparation of the compounds of the present invention. In the formulas, the meanings of the substituents include, for example, X is -CHR3-, -CHR3-alkyl or -CHR3-alkenyl; R1 is heteroaryl, heterocyclic, -R 4 -heteroaryl and -R 4 -heterocycle; R2 is hydrogen, alkyl, alkenyl, aryl, heteroaryl, heterocyclic, alkyl-Y-alkyl, alkyl-Y-alkenyl, alkyl-Y-aryl and substituted alkyl or alkenyl; R4 is an alkyl or alkenyl group which may be interrupted by one or more -O-groups; each R3 is independently H or alkyl; and each Y is independently -O- or -S (O) 0-2-; n is 0-4; and each R is independently alkyl, alkoxy, hydroxy, halo and / or trifluoromethyl. HE which may be interrupted by one or more -O-groups; each R3 is independently H or alkyl; and each Y is independently -O- or -S (O) 0-2-; n is 0-4; and each R is independently alkyl, alkoxy, hydroxy, halo and / or trifluoromethyl. HE which may be interrupted by one or more -O-groups; each R3 is independently H or alkyl; and each Y is independently -O- or -S (O) 0-2-; n is 0-4; and each R is independently alkyl, alkoxy, hydroxy, halo and / or trifluoromethyl. HE